Fate Therapeutics, founded by Rudolf Jaenisch, reported positive data from their ongoing Phase 1 trial of FT516, a natural killer cell-based cancer immunotherapy engineered using an induced pluripotent stem cell (iPSC) platform. Eight of 11 patients with B-cell lymphoma responded favorably to the treatment, with six achieving a complete response.